Research evaluating the effect of Gro Health demonstrates benefits in mental and physical health and wellbeing.
Patients can safely improve symptoms of depression, stress, and anxiety and improve health outcomes associated with type 2 diabetes, prediabetes and obesity.
Saslow, L. R., Summers, C., Aikens, J. E., & Unwin, D. J. (2018). Outcomes of a digitally delivered low-carbohydrate type 2 diabetes self-management program: 1-year results of a single-arm longitudinal study. JMIR diabetes, 3(3), e12
Summers, C., Wu, P. (2021). Supporting mental health during COVID-19 using a digital behaviour change intervention: an open-label, single-arm, pre-post intervention research study. Pending publication.
In collaboration with researchers and clinicians at St Claraspital, the primary purpose of this multi-centre, binational clinical trial is to evaluate the therapeutic potential of the platform on disease-associated parameters in MDD with or without obesity over 6 months.
Secondary purposes include exploring the impact of the platform on blood lipids, uric acid, incretins, plasma BDNF levels, cytokines, gut microbiota composition, markers of leaky gut, metabolic markers, metabolomics, weight, body composition and liver fat fraction, psychometry- brain network activity, hypothalamic-pituitary-adrenal, HPA axis, gastrointestinal tolerance.
In collaboration with researchers and clinicians at The University of British Columbia and The Institute for Personalized Therapeutic Nutrition, the purpose of this study is to assess the feasibility of using a digital intervention for therapeutic carbohydrate restriction.
Our study with King's College London, funded by the The Association for the Study of Obesity, is evaluating the feasibility of the Gro Health app and obesity program in a Tier 3 and Tier 4 obesity setting in London.
Our study with Imperial College London is evaluating the feasibility of the Gro Health app and obesity program in a Tier 3 and Tier 4 obesity setting in London.
Start your journey to better health